Skip to main content

Table 2 The risk factors of recurrence after esophageal variceal eradication by endoscopic therapies

From: The endoscopic ultrasound probe findings in prediction of esophageal variceal recurrence after endoscopic variceal eradication therapies in cirrhotic patients: a cohort prospective study

 

Within 1 year recurrence group

(n = 89)

1–3 years recurrence(n = 54)

Without variceal recurrence group(n = 10)

P value

Gender

 Male(n,%)

58, 65.2

36, 66.7

6, 60

0.91

 Female(n,%)

31, 34.8

18, 33.3

4, 40

Endoscopic treatment

0.02

 EVL(n,%)

39, 43.8

14, 25.9

1, 10

 

 EIS(n,%)

39, 43.8

32, 59.3

9, 90

 EVL + EIS(n,%)

11, 12.4

8, 14.8

0, 0

Variceal diameter(cm)

1.22 ± 0.31

1.20 ± 0.3

0.9 ± 0.2

0.03

Red signs before treatment(Y/N)

68/21

36/18

5/5

0.14

Gastric varices(Y/N)

26/63

13/41

0/10

0.13

Diameter of peri-ECV(mm)

3.7 ± 1.4

2.5 ± 1.1

1.7 ± 0.9

0.0

Existence or not of PFV (Y/N)

57/32

2/52

0/10

0.0

Diameter of PFV(mm)

1.9 ± 1.6

0.1 ± 0.4

0

0.0

Diameter of para-ECV(mm)

6.5 ± 2.2

5.9 ± 1.9

6.9 ± 3.7

0.28

Primary/secondary preventions(n)

15/74

13/41

3/7

0.44

Child-Pugh grade(n,%)

0.04

 A

49, 55.1

39, 72.2

8, 80

 

 B

27, 30.3

14, 25.9

2, 20

 C

13, 14.6

1, 1.9

0, 0

Child-Pugh score

7.3 ± 2.1

6.5 ± 1.4

6.4 ± 0.9

0.025

MELD score

7.1 ± 7.8

6.9 ± 4.9

5.3 ± 2.0

0.72

CT angiography

 Veins around the esophagus(Y/N)

81/8

50/4

9/1

0.93

 Veins around fundus (Y/N)

63/26

38/16

6/4

0.77

 Other collateral vein(Y/N)

12/77

11/43

2/8

0.53

 Portal vein embolus(Y/N)

25/64

10/44

3/7

0.41

With liver cancer/cirrhosis

8/81

9/45

2/8

0.31

Etiology of cirrhosis(n, %)

0.28

 hepatitis B

60, 67.4

33, 61.1

7, 70

 

 hepatitis C

2, 2.2

8, 14.8

1, 10

 alcoholic liver disease

14, 15.7

4, 7.4

1, 10

 nonalcoholic fatty liver disease

6, 6.8

3, 5.6

1, 10

 autoimmune liver disease

6, 6.8

4, 7.4

0, 0

 unknown causes

1, 1.1

2, 3.7

0, 0